Search

Germany used to afford pharmaceutical companies the freedom to set their own prices for products. Recent healthcare reform, however, now means that new medicines must undergo a cost-benefit analysis, which [...]

The article offers information on the significance of the pharmaceutical sector within the healthcare system. It informs that this sector is playing an important role in the providing employer and contributes in the economy. It also talks about pharmaceutical specific tax rates as the reduction in healthcare sector are observed.

The article focuses on the prevalence of counterfeiting medicines supply chains of European Union countries. It states that counterfeiting medicine was considered as ongoing and serious health threat globally. According to World Health Organization (WHO), counterfeit medicines were those medicines fraudulently and deliberately mislabeled, and are products which can cause death.

The article discusses the management of expensive treatments by healthcare technology assessment (HTA), a multidisciplinary field of policy analysis. As stated, Great Britain's HTA the National Institute for Health and Clinical Excellence has caused frustration to the pharmaceutical industry in not recommending payment for Novartis multiple sclerosis drug Gilenya. The article also provides information on accusations of several European HTAs of countries including Germany, France and Sweden.

The article focuses on the impact of innovative Medicines initiative (IMI) on the pharmaceutical innovation in Europe. It mentions that the pharmaceutical industry has invested approximately 27.5 billion eurosin Research and Development but in spite of this huge contribution the regional innovation levels have dropped down in Europe in the year 2011.